Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00255489
NCT00255489
Completed
Phase 1

A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer

AstraZeneca1 site in 1 country36 target enrollmentMay 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsNon-small-cell Lung Cancer
DrugsGefitinib

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Non-small-cell Lung Cancer
Sponsor
AstraZeneca
Enrollment
36
Locations
1
Primary Endpoint
To characterize the safety profile of ZD 1839 in these patients
Status
Completed
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer

Registry
clinicaltrials.gov
Start Date
May 2004
End Date
June 2006
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Provision of written informed consent
  • •Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2
  • •Histologically or cytologically conformed non-small cell lung cancer
  • •Aged 18 or over

Exclusion Criteria

  • •Previous thoracic radiotherapy
  • •Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event
  • •Known hypersensitivity to any component of study medication

Outcomes

Primary Outcomes

To characterize the safety profile of ZD 1839 in these patients

Secondary Outcomes

  • To measure the quality of life compared to baseline
  • To measure the change in disease related symptoms compared to baseline

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 1
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck CancerHead and Neck Cancer
NCT00195078Weill Medical College of Cornell University29
Completed
Phase 1
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate CancerNon-Metastatic Prostate Cancer
NCT00239291AstraZeneca42
Completed
Phase 1
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Carcinoma (NSCLC)
NCT00328562Sidney Kimmel Cancer Center at Thomas Jefferson University13
Completed
Phase 1
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal CancerColorectal Cancer
NCT00026364National Cancer Institute (NCI)22
Completed
Phase 1
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung CancerNon Small Cell Lung Carcinoma
NCT00252798AstraZeneca44